Retatrutide 12 mg reduced urine albumin-to-creatinine ratio by 37.0% compared with placebo at 36 weeks in participants with type 2 diabetes, and by 31.5% at 48 weeks in participants with obesity.
RCT (n=619)
Double-blind
Randomized
Yes
Does retatrutide improve UACR and eGFR in participants with type 2 diabetes mellitus and/or obesity?
Retatrutide may improve kidney parameters such as UACR and eGFR in patients with obesity and/or type 2 diabetes.
Effect estimate: -37.0% change (95% CI -57.3 to -7.0)
Introduction: Obesity and type 2 diabetes mellitus (T2D) increase the risk of kidney disease. This study assessed changes in kidney parameters with retatrutide, an agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Methods: = 338). Both studies were placebo-controlled; the T2D study included dulaglutide 1.5 mg as an active comparator. We assessed change from baseline at week 36 (T2D) and week 48 (overweight/obesity) in urine albumin-to-creatinine ratio (UACR) and eGFR derived from creatinine, cystatin C, or both. Results: (95% CI: 4.9-12.1), respectively. Similar increases in eGFR derived from cystatin C and combined creatinine-cystatin C eGFR were observed. Because most patients had normal albuminuria, the absolute reduction in UACR was modest. Conclusion: Higher doses of retatrutide were associated with reduced UACR in participants with T2D and obesity, and with increased eGFR in participants with obesity but not in those with T2D.
Heerspink et al. (2025) conducted an RCT in Type 2 Diabetes Mellitus and/or Obesity (n=619). Retatrutide vs. Placebo (and dulaglutide 1.5 mg in the T2D trial) was evaluated on Change from baseline in urine albumin-to-creatinine ratio (UACR) at 36 weeks in participants with T2D (-37.0% change, 95% CI -57.3 to -7.0). Retatrutide 12 mg reduced urine albumin-to-creatinine ratio by 37.0% compared with placebo at 36 weeks in participants with type 2 diabetes, and by 31.5% at 48 weeks in participants with obesity.